No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients

  title={No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients},
  author={Claire Bridel and Anand J C Eijlers and Wessel N van Wieringen and Marleen J. A. Koel-Simmelink and Cyra E. Leurs and Menno Michiel Schoonheim and Joep Killestein and Charlotte E. Teunissen},
  journal={Frontiers in Molecular Neuroscience},
Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking. Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients. Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins. Results: In 67 clinically and radiologically well… 
2 Citations

Tables from this paper

Proteomics in Multiple Sclerosis: The Perspective of the Clinician
Proteomics is found to be a highly effective emerging tool that has been providing important findings in the research of MS and for biomarkers of diagnosis, differential diagnosis, conversion of disease courses, disease activity, progression and immunological therapy.
Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis
High-quality parallel reaction monitoring assays covering the main biological processes affected by multiple sclerosis for comparable measurements over time can robustly and stably monitor biological processes in multiple sclerosis patients over time, thus potentially aiding in diagnosis and prognosis, and ultimately in treatment decisions.


Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry
Using high-throughput body fluid profiling by MALDI-TOF mass spectrometry, small proteins and peptides were detected as promising candidate biomarkers for diagnosis and disease progression of MS.
Body fluid biomarkers for multiple sclerosis—the long road to clinical application
Expect biomarker development for MS to be improved and accelerated, with clinical implementation in the near future, in view of the availability and implementation of several standardized protocols to optimize biomarker studies.
Identification of Biomarkers in Cerebrospinal Fluid and Serum of Multiple Sclerosis Patients by Immunoproteomics Approach
An autoreactive anti-transferrin antibody is identified that may have a potential link with the development and progression of MS and is found at high levels also in the serum of MS patients and an immunoenzymatic assay is created to detect it.
A distinctive molecular signature of multiple sclerosis derived from MALDI-TOF/MS and serum proteomic pattern analysis
It is concluded that MALDI-TOF/mass spectrometry, in combination with serum proteomic pattern analysis, could be useful in the diagnosis of MS, and a larger, masked trial to identify proteomic spectral patterns characteristic of relapsing-remitting, primary progressive and secondary progressive variants of MS is justified.
Protein expression profiles in pediatric multiple sclerosis: potential biomarkers
Results show that 2-DE in combination with mass spectrometry is a highly sensitive technique for the identification of blood-based biomarkers and could lead to a new panel of diagnostic and prognostic markers in pediatric MS.
Autophagy-related gene16L2, a potential serum biomarker of multiple sclerosis evaluated by bead-based proteomic technology
Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients.
A variety of proteins were found to be differentially expressed in the serum between MS, NMO, and normal subjects using 2-DE: Ig lambda, Hp2, and keratin 83 were identified as potential diagnostic markers or treatment targets for MS or NMO.
Affinity proteomic profiling of plasma, cerebrospinal fluid, and brain tissue within multiple sclerosis.
The affinity proteomic translation of profiles discovered by profiling human body fluids and tissue provides a powerful strategy to suggest additional candidates to studies of neurological disorders.
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
A consensus report on recommendations for CSF collection and biobanking is presented, formed by the BioMS-eu network forCSF biomarker research in multiple sclerosis, and focuses on CSf collection procedures, preanalytical factors, and high-quality clinical and paraclinical information.